title: SIRT1 modulation as a novel approach to the treatment of diseases of aging.
authors.affiliation: Sirtris, A GSK Company, 200 Technology Square, Cambridge, Massachusetts 02139, United States. cblum@sirtrispharma.com
authors.forename: Charles A
authors.initials: CA
authors.lastname: Blum
authors.forename: James L
authors.initials: JL
authors.lastname: Ellis
authors.forename: Christine
authors.initials: C
authors.lastname: Loh
authors.forename: Pui Yee
authors.initials: PY
authors.lastname: Ng
authors.forename: Robert B
authors.initials: RB
authors.lastname: Perni
authors.forename: Ross L
authors.initials: RL
authors.lastname: Stein
mesh_terms: D000375:Aging; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use; D002384:Catalysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D020536:Enzyme Activators / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007700:Kinetics; D056564:Sirtuin 1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D013379:Substrate Specificity
chemical_list: D000893:Anti-Inflammatory Agents; D019440:Anti-Obesity Agents; D020536:Enzyme Activators; D007004:Hypoglycemic Agents; D056564:Sirtuin 1